Renal function as a predictor of long-term graft survival in renal transplant patients

Nephrology Dialysis Transplantation

Volumn 18, Issue SUPPL. 1, 2003, Pages

  First, M Roy ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Rejection; Renal function; Renal transplantation; Survival tacrolimus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

CLINICAL TRIALS; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS; TIME FACTORS;

EID: 0038684553     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590
2. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443
3. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746
4. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841
5. Gonwa T, Rice K, Langnas A et al. Sirolimus vs MMF-first report of a U.S. multicenter kidney transplant study with tacrolimus combination therapy. Am J Transplant 2002; 2 (Suppl 3): 471 (Abstract 1320)
6. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
7. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318
8. Fitzsimmons W, Thompson D, Hariharan S, Van Veldhuisen P. Serum creatinine as a surrogate endpoint for graft loss in kidney transplantation: validation efforts from multicentre trials. Am J Transplant 2002; 2 (Suppl 3): 272 (Abstract 533)
9. Tejani A, Stablein D, Ho P. Calculated creatinine clearance (CCC) as the most promising candidate surrogate end point for clinical trials. Am J Transplant 2002; 2 (Suppl 3): 256 (Abstract 472)
10. Gourishankar S, Hunsicker L, Jhangri G, Cockfield S, Halloran P. The stability of renal function (the slope of the glomerular filtration rate) in renal transplants is improving. Am J Transplant 2002; 2 (Suppl 3): 412 (Abstract 1091)
11. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782